BMY Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 17.96% compared to Bristol Myers Squibb Co.'s net margin of 39.21%. Bristol Myers Squibb Co.'s return on equity of 34.7% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Bristol Myers Squibb Co. has a consensus price target of $54.50, signalling upside risk potential of 0.57%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 6.51%. Given that Gilead Sciences, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Gilead Sciences, Inc. is more attractive than Bristol Myers Squibb Co..

Bristol Myers Squibb Co. has a beta of 0.296, which suggesting that the stock is 70.363% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

Bristol Myers Squibb Co. has a quarterly dividend of $0.62 per share corresponding to a yield of 4.58%. Gilead Sciences, Inc. offers a yield of 2.54% to investors and pays a quarterly dividend of $0.79 per share. Bristol Myers Squibb Co. pays 54.44% of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences, Inc.'s is not.

Bristol Myers Squibb Co. quarterly revenues are $12.2B, which are larger than Gilead Sciences, Inc. quarterly revenues of $7.8B. Bristol Myers Squibb Co.'s net income of $2.2B is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Bristol Myers Squibb Co.'s price-to-earnings ratio is 18.30x while Gilead Sciences, Inc.'s PE ratio is 19.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol Myers Squibb Co. is 2.30x versus 5.38x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 17.96% compared to Bristol Myers Squibb Co.'s net margin of 21.47%. Bristol Myers Squibb Co.'s return on equity of 34.7% beat Johnson & Johnson's return on equity of 33.27%.

Bristol Myers Squibb Co. has a consensus price target of $54.50, signalling upside risk potential of 0.57%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 1.42%. Given that Johnson & Johnson has higher upside potential than Bristol Myers Squibb Co., analysts believe Johnson & Johnson is more attractive than Bristol Myers Squibb Co..

Bristol Myers Squibb Co. has a beta of 0.296, which suggesting that the stock is 70.363% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Bristol Myers Squibb Co. has a quarterly dividend of $0.62 per share corresponding to a yield of 4.58%. Johnson & Johnson offers a yield of 2.49% to investors and pays a quarterly dividend of $1.30 per share. Bristol Myers Squibb Co. pays 54.44% of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol Myers Squibb Co. quarterly revenues are $12.2B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Bristol Myers Squibb Co.'s net income of $2.2B is lower than Johnson & Johnson's net income of $5.2B. Notably, Bristol Myers Squibb Co.'s price-to-earnings ratio is 18.30x while Johnson & Johnson's PE ratio is 19.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol Myers Squibb Co. is 2.30x versus 5.43x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 17.96% compared to Bristol Myers Squibb Co.'s net margin of 31.72%. Bristol Myers Squibb Co.'s return on equity of 34.7% beat Eli Lilly & Co.'s return on equity of 106.26%.

Bristol Myers Squibb Co. has a consensus price target of $54.50, signalling upside risk potential of 0.57%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 2.03%. Given that Eli Lilly & Co. has higher upside potential than Bristol Myers Squibb Co., analysts believe Eli Lilly & Co. is more attractive than Bristol Myers Squibb Co..

Bristol Myers Squibb Co. has a beta of 0.296, which suggesting that the stock is 70.363% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Bristol Myers Squibb Co. has a quarterly dividend of $0.62 per share corresponding to a yield of 4.58%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Bristol Myers Squibb Co. pays 54.44% of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol Myers Squibb Co. quarterly revenues are $12.2B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Bristol Myers Squibb Co.'s net income of $2.2B is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Bristol Myers Squibb Co.'s price-to-earnings ratio is 18.30x while Eli Lilly & Co.'s PE ratio is 52.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol Myers Squibb Co. is 2.30x versus 16.44x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 17.96% compared to Bristol Myers Squibb Co.'s net margin of 38.89%. Bristol Myers Squibb Co.'s return on equity of 34.7% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Bristol Myers Squibb Co. has a consensus price target of $54.50, signalling upside risk potential of 0.57%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $789.90 which suggests that it could grow by 2.86%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Bristol Myers Squibb Co..

Bristol Myers Squibb Co. has a beta of 0.296, which suggesting that the stock is 70.363% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Bristol Myers Squibb Co. has a quarterly dividend of $0.62 per share corresponding to a yield of 4.58%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.88 per share. Bristol Myers Squibb Co. pays 54.44% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bristol Myers Squibb Co. quarterly revenues are $12.2B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Bristol Myers Squibb Co.'s net income of $2.2B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Bristol Myers Squibb Co.'s price-to-earnings ratio is 18.30x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bristol Myers Squibb Co. is 2.30x versus 5.94x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.